biib054
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02459886)
Timeline
Indications
Mechanism of action
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Recombinant human antibody that prevents alpha-synuclein cell-to-cell transmission, and thus propagation of Lewy body pathology
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3833330 ↗
Also known as
- biib054
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03716570 | Phase 1 | Mar 12, 2019 | Biogen |
| NCT03318523 | Phase 2 | Jan 10, 2018 | Biogen |
| NCT02459886 | Phase 1 | Jul 1, 2015 | Biogen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 3 | 3 | 2 | 2015 |
1 organizations
Page 1 / 1